Rochester, Minn.-based Mayo Clinic BioPharma Diagnostics has partnered with artificial intelligence-powered spatial biology company Nucleai to support drug development using AI.
Under the partnership, Mayo Clinic's multimodal datasets, laboratories and clinical expertise will combine with Nucleai's AI platform to develop new offerings for biomarker discovery and validation, end-to-end spatial biology testing and algorithm deployment for clinical trials and diagnostic use, according to a June 4 press release from Nucleai.
The aim is for both entities to create new digital pathology solutions, technologies and services to support drug development and clinical practice.